OMEROS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
OMEROS CORP (OMER) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-31
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $6.20M, a 1140.00% increase from fiscal 2024.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $500.00K, a 400.00% increase from fiscal 2023.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- OMEROS CORP share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $200.00K, a 97.44% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $6.20M 10-K · filed 2026-03-31 |
| 2024-12-31 | $500.00K 10-K · filed 2026-03-31 |
| 2023-12-31 | $100.00K 10-K · filed 2026-03-31 |
| 2022-12-31 | $200.00K 10-K · filed 2025-03-31 |
| 2021-12-31 | $7.80M 10-K · filed 2024-04-01 |
| 2018-12-31 | $11.36M 10-K · filed 2019-03-01 |
| 2017-12-31 | $16.40M 10-K · filed 2019-03-01 |
| 2016-12-31 | $13.60M 10-K · filed 2019-03-01 |
| 2015-12-31 | $3.90M 10-K · filed 2018-03-01 |
| 2014-12-31 | $2.90M 10-K · filed 2017-03-16 |
| 2013-12-31 | $1.10M 10-K · filed 2016-03-15 |
| 2012-12-31 | $578.00K 10-K · filed 2015-03-16 |
| 2011-12-31 | $2.10M 10-K · filed 2014-03-13 |
| 2010-12-31 | $1.40M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |